GHRP-6

Growth Hormone Releasing Peptide-6

GHRP-6 (Growth Hormone Releasing Peptide-6) is a gh & growth research compound. GHRP/ghrelin agonist that also strongly stimulates hunger — useful when appetite/bulking is the goal.

How GHRP-6 works

GHRP/ghrelin agonist that also strongly stimulates hunger — useful when appetite/bulking is the goal.

Proposed benefits

Researched for lean-mass support, recovery, sleep depth, connective-tissue repair and improved body composition via the GH/IGF-1 axis.

Where to get GHRP-6

The evidence for GHRP-6

Graded by what exists behind each claim.

✅ Clinically validated

• Like GHRP-2, characterized in humans as a GH secretagogue in diagnostic and early clinical work, with published dose-response data. No efficacy trial for any performance or body-composition endpoint.

📊 Correlative data

• The appetite effect is the defining reported feature — far stronger than GHRP-2 and dramatically stronger than ipamorelin. That makes it useful to someone struggling to eat and intolerable to someone in a deficit.
• Also raises cortisol and prolactin.

🧪 Theoretical / extrapolated

• A ghrelin-receptor agonist that engages the appetite arm of ghrelin signaling much more strongly than its relatives.
• Ghrelin is the hunger hormone, so a hunger response is the mechanism working, not a side effect — which is the honest framing, and also the reason the search for selective agonists produced ipamorelin.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What GHRP-6 actually does

Write the sequence out and the molecule explains itself. GHRP-6 is His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, with a measured molecular weight of 872.44 Da Cabrales 2013. Written the way sequences are usually written, one letter per residue, it is HWAWFK — and that six-letter string hides the two design decisions that make it a drug rather than a snack.

The three-letter form loses the same information, and this is the form every database and certificate stores. Written in the convention that lists residues without stereochemistry, GHRP-6 reads His-Trp-Ala-Trp-Phe-Lys. Every residue in that string is correct. What the string cannot carry is the backbone geometry at positions 2 and 5, and that geometry is the entire reason a 6-residue peptide is not destroyed on contact with plasma — peptidase recognition depends on the configuration of the residues flanking the bond being cut. Whether the growth hormone secretagogue receptor also requires that orientation is an inference from the fact that the chemists who built this peptide chose it, rather than something this page can point at a published binding constant for.

Decision one: residues 2 and 5 are D-amino acids. D-Trp at position 2 and D-Phe at position 5 are mirror images of the natural residues. Peptidases evolved to cut an all-L backbone, and they recognize the geometry either side of the bond they hydrolyze. Putting an unnatural stereocentre on both flanks of the core is a deliberate block on that recognition, and it is why a 6-residue peptide survives in plasma at all.

Decision two: the C-terminus is an amide, not an acid. The -NH2 at the end removes the free carboxylate that carboxypeptidases grip. Between the amide cap and the two D-residues, this molecule has had its two most obvious degradation routes closed by design. None of that is visible in HWAWFK, which is why the one-letter form is the wrong way to think about this compound and why a vendor certificate quoting a mass alone does not establish that the D-residues are actually D.

The receptor came second, and this peptide is why it was found. GHRP-6 was the probe used to clone the growth hormone secretagogue receptor from pituitary and from the arcuate, ventromedial and infundibular hypothalamus of swine and humans — a G protein-coupled receptor whose discoverers wrote that the secretagogues appeared to mimic an undiscovered hormone Howard 1996. Three years later that hormone was isolated from stomach and named ghrelin Kojima 1999. The ordering is worth holding onto: the synthetic drug existed first, the receptor was found using it, and the natural ligand was found last. GHRP-6 is not an analog of ghrelin. Ghrelin is the endogenous answer to a question GHRP-6 asked.

The mechanism's hard ceiling, measured in people. GHRP-6 is routinely described as a growth hormone releaser in its own right. It is not. Nine healthy men aged 20 to 30 years received either saline or a specific GHRH antagonist, followed by a GHRP-6 bolus Pandya 1998. Blocking endogenous GHRH cut the maximal growth hormone rise from 33.8 to 6.2 micrograms per liter, P less than 0.0001, and the area under the curve from 1701 to 376, P less than 0.001. Roughly four fifths of the effect required the hypothalamus to be releasing its own GHRH. This compound amplifies a signal it does not generate, so anything that flattens hypothalamic GHRH output — somatostatin tone, negative feedback from rising IGF-1, age — puts a lid on it that no increase in dose can lift.

And there is an endogenous off-switch on the same receptor that almost nobody dosing this compound has heard of. Liver-expressed antimicrobial peptide 2, LEAP2, is produced in liver and small intestine, fully inhibits activation of the ghrelin receptor, and blocks ghrelin's major effects in vivo including food intake and growth hormone release Ge 2018. Its secretion is suppressed by fasting. That single sentence is the mechanistic justification for the folklore that GHRP-6 must be taken on an empty stomach: eating raises the concentration of a natural antagonist sitting on the receptor you are trying to hit.

Cell, rodent, human — and where it stops

Step one, at the receptor. The growth hormone secretagogue receptor was cloned from pituitary and hypothalamus in swine and humans, and its pharmacological characterization was done with this class of peptide Howard 1996. The natural ligand, ghrelin, was identified from stomach three years afterwards Kojima 1999. This is unusually solid ground for a research-market peptide: the target is a defined human receptor with a known endogenous ligand.

Step two, in humans, acutely, and the human data is real. Two independent studies in healthy men, 9 subjects each, and both measured something checkable. The first gave an intravenous bolus with and without a GHRH antagonist and quantified the growth hormone response Pandya 1998. The second gave single intravenous boluses at three dose levels and measured plasma concentrations by a validated liquid chromatography-mass spectrometry method with a carbon-13-labeled internal standard Cabrales 2013. Compared to most compounds in this catalog, that is a luxurious evidence base. Compared to what people do with the compound, it is almost irrelevant.

Step three, in humans, chronically: zero. There is no randomized trial of GHRP-6 for body composition, lean mass, recovery, sleep or appetite, at any duration. Every published human exposure to this molecule is a single intravenous bolus in an endocrine challenge setting, in a small group of young men, under monitoring. This site's own protocol describes 1 to 3 daily subcutaneous doses for 3 to 6 months. Those two things have nothing in common except the molecule.

The obstacles, one at a time. (1) Route. All published pharmacokinetics are intravenous Cabrales 2013; the market uses subcutaneous. No subcutaneous absorption profile has ever been published, and for a compound whose entire purpose is producing a pulse, the absorption curve is the pharmacology — a slow subcutaneous depot converts a spike into a plateau, and growth hormone secretion is physiologically pulsatile. (2) Duration. Single boluses cannot show whether the response persists, and the mechanism gives a specific reason to worry that it will not, because the effect requires endogenous GHRH Pandya 1998 and endogenous GHRH is under negative feedback from the IGF-1 that a working course raises. (3) Population. Healthy men aged 20 to 30 years, a group with intact hypothalamic output; the middle-aged buyer has less of the signal this compound multiplies. (4) The endpoint gap. Nobody has measured body composition, strength or sleep on this compound in any controlled setting, so the entire performance case is an inference from an acute hormone pulse. (5) The fed state has never been controlled for in a published GHRP-6 study, and the discovery of a meal-responsive endogenous antagonist at the same receptor Ge 2018 means that the fed-versus-fasted difference could be large and nobody has measured it.

GHRP-6 pharmacokinetics — how much of it actually gets in

This site's card says the half-life is roughly 15 to 60 minutes. The published human study says something different, and the difference matters.

The measurement. Nine male healthy volunteers received single intravenous boluses at three dose levels, with plasma quantified by a validated LC-MS assay against a carbon-13-labeled internal standard Cabrales 2013. Disposition fitted a bi-exponential model with an R-squared above 0.99, better than a one-compartment fit by Akaike criterion in every subject. Averaged across the doses, the distribution half-life was 7.6 plus or minus 1.9 minutes and the elimination half-life was 2.5 plus or minus 1.1 hours. The lower limit of quantification, 5 nanograms per milliliter, was reached at 12 hours in every subject, which was enough to model over 85% of the area under the curve. Exposure increased roughly in proportion to dose.

So the honest statement is a two-phase one. The 7.6-minute distribution phase is the number that matches the 15-to-60-minute folklore and it is the phase in which the peptide leaves the blood for the tissues. The 2.5-hour elimination phase is roughly three to ten times longer than this site currently says, and it is the number that governs whether twice-daily and three-times-daily protocols overlap.

The finding nobody has explained. In 4 of the 9 subjects the authors observed atypical concentration spikes during the elimination phase Cabrales 2013 — the plasma level went back up when it should only have gone down. Nearly half the sample. Nothing published accounts for it. The candidate explanations are release from a tissue binding site, enterohepatic recirculation, or an assay artefact, and distinguishing them would require a repeat study nobody has run. It is worth naming because it means the exposure profile of this compound is not fully predictable even after an intravenous dose in a controlled setting.

What degrades it, and what does not. The two D-amino acids and the C-terminal amide close the standard peptidase routes, which is why a hexapeptide has a multi-hour terminal phase at all. What remains is endopeptidase cleavage within the L-residue stretches and ordinary renal handling of a sub-1000 Da molecule.

The oral barrier. Swallowed, this peptide meets gastric acid, then pancreatic proteases, then brush-border peptidases, and anything absorbed faces hepatic first-pass extraction. The D-residues and the amide cap are exactly the modifications that improve survival on that route, which is why oral administration of this hexapeptide has been attempted at all — but no oral bioavailability figure appears in the study that characterized its pharmacokinetics, which was intravenous only Cabrales 2013.

The injectable comparator, and the gap this page cannot close. Every published number above came from an intravenous bolus. The subcutaneous injection this compound is actually sold for adds an absorption phase whose rate constant has never been measured, so the peak concentration, the time to peak and the sharpness of the growth hormone pulse are all unpublished for the route everybody uses.

What would have to be true, and how you would know it was not

Four predictions. The third is the one that cuts against the compound and it is the reason people stop reporting results at week 10.

1. IGF-1 should rise, and it is the only efficacy readout worth buying. Growth hormone itself is pulsatile and a single random draw is close to useless. IGF-1 (Insulin-like Growth Factor 1) integrates the pulses over days, so draw it at baseline and again at 6 to 8 weeks. If a course of a growth hormone secretagogue does not move IGF-1, either the vial is not what it claims or the dose is not producing pulses, and no amount of subjective report substitutes for that number.

2. Fasting insulin and HbA1c are the safety half of the same draw. Everything unwanted about a sustained growth hormone elevation runs through insulin resistance. Take fasting insulin and HbA1c with the IGF-1 draw. HbA1c integrates 2 to 3 months, so on a 3-month cycle it is retested once at the end; fasting insulin moves far sooner and is the earlier warning.

3. The prediction that cuts against the compound: the response should fade, and IGF-1 should show it. Four fifths of this peptide's growth hormone effect requires endogenous hypothalamic GHRH Pandya 1998, and endogenous GHRH is suppressed by the same IGF-1 a working course raises. That is a closed negative-feedback loop with the compound sitting inside it. Prediction: on an unchanged dose, IGF-1 rises between baseline and week 6 and then plateaus or declines between week 6 and week 12. Three draws instead of two tests it. If IGF-1 keeps climbing linearly the mechanism above is wrong, which would be a genuinely useful result.

4. Cortisol and prolactin are an open measurement, not a known effect. The hexapeptide secretagogues are widely reported to lift adrenocorticotropic and lactotroph output alongside growth hormone, and this site's own correlative tier says so. What does not exist is a published dose-response for GHRP-6 at self-administered subcutaneous doses. So draw morning cortisol and prolactin at baseline and at 6 weeks and treat the result as data rather than confirmation. A dozen paired draws would be the first such series in existence.

What nobody has tested yet

Five experiments, and the first is the one this compound most deserves.

1. Nobody has measured LEAP2 in anybody using a GHRP. An endogenous antagonist of this exact receptor, produced in liver and gut and suppressed by fasting, fully blocks ghrelin's activation of the receptor and blocks growth hormone release in vivo Ge 2018. That makes it the obvious explanation for two things this market takes on faith: why fasted dosing works better, and why the appetite response varies so wildly between people. The experiment is one dose given fasted and the same dose given after a meal in the same person, with paired growth hormone curves and paired LEAP2 concentrations. It has never been done with any growth hormone secretagogue, and it would be the first mechanistic explanation this practice has ever had.

2. Nobody has published subcutaneous pharmacokinetics. Every number in existence is intravenous Cabrales 2013. Six timed draws after one subcutaneous dose would produce the absorption profile that every dosing protocol on the internet silently assumes.

3. Nobody has explained the concentration spikes. They appeared in 4 of 9 subjects during the elimination phase Cabrales 2013 and no follow-up has been published in the years since. A repeat study with denser sampling and a bile or urine arm would distinguish tissue release from recirculation, and would tell half of all users why their exposure is not what the model says.

4. Nobody has tested whether the growth hormone response survives repeated dosing. Every human study is a single bolus. A 3-dose series — day 1, day 30, day 90, same dose, same time of day, same fasted state, growth hormone sampled over 2 hours each time — would settle the tachyphylaxis question for the entire secretagogue class, and it is within reach of a determined self-experimenter with a clinic.

5. Nobody has checked whether the D-residues are actually D. The stereochemistry at positions 2 and 5 is the reason this molecule survives in plasma, and mass spectrometry cannot see it: an all-L HWAWFK amide has the identical formula and the identical 872.44 Da mass Cabrales 2013. Chiral analysis of the hydrolysate is the assay that distinguishes them, it is routine, and it has never been reported for a research-market vial. A batch built with L-tryptophan and L-phenylalanine would pass every certificate of analysis this market issues, and would be expected to lose the protection that gives this molecule its 2.5-hour terminal phase in the first place.

GHRP-6 — its own safety story, not its class's

The class block on this page is the growth hormone and IGF-1 story, and for once most of it applies, because this compound really does raise growth hormone in people Pandya 1998. What the class block cannot give you is the four things that are specific to this hexapeptide.

1. The hunger is the drug working, and that is exactly why it is the risk. This is an agonist at the receptor for the hormone that signals hunger Kojima 1999 Howard 1996. An appetite response is not a side effect to be tolerated until it settles — it is the receptor doing its primary job. The practical consequence is asymmetric: for somebody struggling to eat, it is the reason to choose this over its selective relatives; for somebody in a deficit it reliably destroys the deficit, and no dose adjustment separates the hunger from the growth hormone pulse because they are the same receptor.

2. The entire human safety record is 18 men, each given a single intravenous dose. Nine in the GHRH-antagonist study Pandya 1998 and nine in the pharmacokinetic study Cabrales 2013. No published study has given this compound to anybody more than once. This site's protocol field describes daily dosing for 3 to 6 months. There is no observation period anywhere in the literature long enough for a chronic adverse effect of GHRP-6 to have been recorded, which is a different statement from saying none occurs.

3. The unpredictable exposure is a safety finding, not just a pharmacokinetic curiosity. Plasma concentrations rose again during the elimination phase in 4 of 9 subjects Cabrales 2013. A person dosing 3 times daily on the assumption of a clean decay curve may be stacking exposure in a way the model does not predict, and nobody knows which people do it or why.

4. The adrenal and lactotroph question is open at these doses. Reports of cortisol and prolactin elevation attach to this peptide family throughout the literature, and there is no published dose-response for GHRP-6 at the microgram-scale subcutaneous doses people actually use. A persistent prolactin elevation has consequences for libido and, in men, for testosterone; a persistent cortisol elevation works directly against the muscle the compound is being taken for. Both are on a standard panel and neither is routinely measured.

Sources read for this page

• Cabrales A, Gil J, Fernandez E, Valenzuela C, Hernandez F, Garcia I, Hernandez A, Besada V, Reyes O, Padron G, et al. Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. European Journal of Pharmaceutical Sciences 2013 · PMID 23099431
• Pandya N, et al. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. Journal of Clinical Endocrinology and Metabolism 1998 · PMID 9543138
• Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996 · PMID 8688086
• Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999 · PMID 10604470
• Ge X, et al. LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor. Cell Metabolism 2018 · PMID 29233536

GHRP-6 — safety, predicted from mechanism

GHRP-6 — interference & stacking

Bloodwork to run alongside GHRP-6

Baseline first, then again at 8–12 weeks.

The “Running GH Peptides or MK-677” panel covers these in one order — 9 markers, $132.30 with the discount applied.

Check results you already have → · All 103 markers A–Z

GHRP-6 — frequently asked questions

What GHRP-6 is used for

GHRP-6 appears under 1 goal in the goal router.

Related GH & Growth compounds

← Explore the full Protocol Vault

↑ Back to on this page